Pharmaceutical Technology, Apr 1, 2011 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Apr 1, 2011
Special Feature
Audio: Excipient Functionality and Continuous Manufacturing
Listen to roundtables from the 2011 ExcipientFest/IPEC conference, addressing developing issues in excipient functionality and continuous manufacturing.
Featured Content
Exploring Excipient Functionality
By Patricia Van Arnum
This technical forum is part of a special issue on Solid Dosage and Excipients.
Innovations in Tablet Coating
Representatives from Pfizer R&D, DEM Solutions, Colorcon, and ARmark Authentication Technologies provide insight into recent tablet-coating technologies.
Oral-Absorption-Enhancing Drug-Delivery Technology
By Edwin G. Walsh , John S. Fox , Thomas W. Leonard
The authors examine an oral-absorption-enhancement technology based on surface-active materials to increase apical membrane fluidity in vitro.
Correlating Die-Filling Performance with Powder Properties
By Tim Freeman
The author explains how to gain an understanding of the relationships between powder characteristics and process performance to match filling-machine geometry to the demands of specific formulations.
Risk Assessment for Excipients for Enhanced Patient Safety
By Dale Carter
The author describes key considertions for a complete risk-assessment model and provides insight into a pending IPEC guideline in this area.
Total Excipient Control: A Pathway to Increased Patient Safety
By David R. Schoneker
The author focuses on how industry can build a system for Total Excipient Control.
Exploring Nanotechnology in Drug Delivery
By Patricia Van Arnum
Nanotechnology often is associated with parenteral drug delivery, particularly for anticancer therapies, but it also has applications in oral drug delivery


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Click here